AKT1 and breast cancer: Our study also validates the involvement of PGE2 signalling through EP4 receptor, and the subsequent PI3K/Akt pathways in these processes, further validating the use of EP4 receptor antagonists as a potential therapeutic target in COX2-high breast cancer patients.